Abstract: Symmetrically and asymmetrically branched homopolymers are modified at the surface level with functional groups that enable forming aggregates with water insoluble or poorly water soluble pharmaceutically active agents (PAA). The aggregates formed are specifically induced by interaction of PAA and homopolymer and are different from aggregates that are formed by the polymer alone in the absence of the PAA or by the PAA alone in the absence of the polymer. Such aggregates can be used to improve drug solubility, stability, delivery and efficacy.

Abstract: The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising an arylsulfatase A (ASA) protein, salt, and a polysorbate surfactant for the treatment of Metachromatic Leukodystrophy Disease.

Abstract: This invention is directed to a biodegradable polymer that can be degraded in vivo. The biodegradable polymer comprises a biodegradable polymer segment having at least a biodegradable bond and two or more cationic components, wherein each of said cationic components is covalently attached to the biodegradable polymer segment and the two cationic components/molecules are separated by at least one biodegradable bond in the backbone. The biodegradable polymer can be used for targeting desired ceils in vivo including T cells, NK (natural killer) ceils, cancer cells, or a combination thereof, delivering genes, DNA, oligodeoxynucleotide, oligonucleotide, RNA, mRNA, RNAi, siRNA, microRNA, protein, peptide, antibody, fragment of an antibody, small molecule drug including chemotherapy drugs, or other bioactive agents into cells, or being used as a vaccine or drug for treating a disease such as a cancer in a subject.

Abstract: The present disclosure provides a method, computer system and computer program product for generating a conversation content. According to the method, a rule corresponding to a first component of a user interface can be obtained, wherein the first component represents one or more resources provided to a user, an operation for the first component can be determined based on the rule and a feature of the first component, a virtual component tree can be constructed according to the operation, wherein the virtual component tree depicts components to be included in the user interface and relationship between the components; and the user interface can be rendered based on the virtual component tree.

Abstract: A medical device includes a display area that has a thin panel having a substantially flat front surface portion, a translucent layer on a back surface of the thin panel, a layer of text or graphics on a back surface of the translucent layer, and arranged so that the text or graphics is not visible to a user on the front side when light is not provided from inside the device housing, a switch to allow a user to select a first mode or a second mode for the device, and circuitry arranged to energize one or more light sources to provide light from behind the thin panel when the device is in the first mode, and to thereby make visible the text or graphics when the device is in the first mode.

Abstract: The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes (e.g., recombinant human arylsulfatase A (rhASA)) for effective treatment of lysosomal storage diseases (e.g., Metachromatic Leukodystrophy Disease). In some embodiments, the present invention includes a stable formulation for intrathecal administration comprising an ASA protein and a poloxamer, wherein less than 5% of the ASA protein exists in aggregated form.

Abstract: Symmetrically and asymmetrically branched homopolymers are modified at the surface level with functional groups that enable forming aggregates with water insoluble or poorly water soluble pharmaceutically active agents (PAA). The aggregates formed are specifically induced by interaction of PAA and homopolymer and are different from aggregates that are formed by the polymer alone in the absence of the PAA or by the PAA alone in the absence of the polymer. Such aggregates can be used to improve drug solubility, stability, delivery and efficacy.

Abstract: Symmetrically and asymmetrically branched homopolymers are modified at the surface level with functional groups that enable forming aggregates with a taxane, such as, paclilaxei and its derivatives, which are water insoluble or poorly water soluble. The aggregates are formed by interaction of a taxane and a homopolymer. Such aggregates improve drug solubility, stability, delivery and efficacy.

Abstract: The present invention provides, among oilier things, compositions and methods for CNS delivery of lysosomal enzymes (e.g., recombinant human arylsulfatase A (rhASA)) for effective treatment of lysosomal storage diseases (e.g. Metachromatic Leukodystrophy Disease), In some embodiments, the present invention includes a stable formulation for intrathecal administration comprising an ASA protein and a poloxamer, wherein less than 3% of the ASA protein exists in aggregated form.

Abstract: The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising an arylsulfatase A (ASA) protein, salt, and a polysorbate surfactant for the treatment of Metachromatic Leukodystrophy Disease.

Abstract: The present invention provides an effective and less invasive approach for direct delivery of therapeutic agents to the central nervous system (CNS). In some embodiments, the present invention provides methods including a step of administering intrathecally to a subject suffering from or susceptible to a lysosomal storage disease associated with reduced level or activity of a lysosomal enzyme, a composition comprising a replacement enzyme for the lysosomal enzyme.

Abstract: A system for assisting a rescuer includes: a chest compression sensor configured to sense movement of the patient's chest and a second sensor configured to sense information indicative of whether the rescuer's hand is in contact with or is not in contact with the patient's chest. The second sensor is configured to be positioned on the patient's chest at a location corresponding to a location of the rescuer's hand when delivering chest compressions to the patient's chest. The system also includes a feedback device and a computing unit. The computing unit is configured to cause the feedback device to provide chest compression feedback based on a determined chest compression rate and chest compression depth and to provide chest release feedback based on a determination of whether the rescuer is releasing the chest in between chest compressions.

Abstract: The invention provides compositions and methods for effective lysosomal targeting mediated by SORT1. In particular, the compositions and methods provided by the invention may be used to treat lysosomal storage diseases such as Sanfilippo syndrome type B.

Abstract: Embodiments of the present disclosure relate to reuse ongoing reusable Ajax requests. According to the method, one or more processors receive a first Ajax request in a web application. The method further includes detecting at least one ongoing Ajax request comprising a second ongoing reusable Ajax request. The second ongoing Ajax request may be substantially similar to the first Ajax request. The method further includes receiving the second ongoing reusable Ajax request from a server of the web application. The method further includes executing a call-back function of the second ongoing reusable Ajax request.

Abstract: The present invention provides, among other things, compositions and methods for CNS delivery of lysosomal enzymes for effective treatment of lysosomal storage diseases. In some embodiments, the present invention includes a stable formulation for direct CNS intrathecal administration comprising an iduronate-2-sulfatase (I2S) protein, salt, and a polysorbate surfactant for the treatment of Hunters Syndrome.

Abstract: A multi-mode electronic medical device for providing resuscitative therapy. The device comprising a housing having a front side positioned to be visible to a user of the device during use, and a user-selectable input to allow the user to select between a basic life support mode and an advanced life support mode. The device further comprising a display on the front of the device housing configured to display a first set of text and/or graphics in the basic life support mode and to display a second set of text and/or graphics, which are more complete than the first set of text and/or graphics, when the device is switched to the advanced life support mode via the user-selectable input. Additionally, the device comprising circuitry configured to control the display based on whether the medical device is operating in the basic life support mode or the advanced life support mode.

Abstract: The present invention provides an effective and less invasive approach for direct delivery of therapeutic agents to the central nervous system (CNS). In some embodiments, the present invention provides methods including a step of administering intrathecally to a subject suffering from or susceptible to a lysosomal storage disease associated with reduced level or activity of a lysosomal enzyme, a composition comprising a replacement enzyme for the lysosomal enzyme.